<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819636</url>
  </required_header>
  <id_info>
    <org_study_id>LIPO-2</org_study_id>
    <secondary_id>2012-A01645-38</secondary_id>
    <nct_id>NCT01819636</nct_id>
  </id_info>
  <brief_title>Effects Of Consumption Of A Highly Mineralized Sodium Bicarbonated Water On Blood Lipid Profile</brief_title>
  <official_title>Effects Of Consumption Of A Highly Mineralized Sodium Bicarbonated Water On Blood Lipid Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neptune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neptune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the beneficial effect of the short term consumption of the
      highly mineralized bicarbonated sodium water on blood lipid parameters compared to a low
      mineralized water.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting plasma triglyceride</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma total cholesterol</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma triglyceride</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Area Under Curve (iAUC) between T0 and T480min of plasma triglycerides</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma High Density Lipoprotein cholesterol</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma Low Density Lipoprotein cholesterol</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Area Under Curve (iAUC) between T0 and T480min of plasma total cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Area Under Curve (iAUC) between T0 and T480min of plasma High Density Lipoprotein cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Area Under Curve (iAUC) between T0 and T480min of plasma Low Density Lipoprotein cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax between T0 and T480min of plasma triglyceride</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax between T0 and T480min of plasma High Density Lipoprotein cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax between T0 and T480min of plasma total cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax between T0 and T480min of plasma Low Density Lipoprotein cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta peak between T0 and T480min of plasma Low Density Lipoprotein cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta peak between T0 and T480min of plasma High Density Lipoprotein cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta peak between T0 and T480min of plasma total cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic between T0 and T480min of plasma Low Density Lipoprotein cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic between T0 and T480min of plasma High Density Lipoprotein cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic between T0 and T480min of plasma total cholesterol</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic between T0 and T480min of plasma triglycerides</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta peak between T0 and T480min of plasma triglycerides</measure>
    <time_frame>0 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Amino Transferase</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Amino Transferase</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic urea</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic creatinine</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic potassium</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic sodium</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic Chloride</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma Glutamyl Transferase</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>PCSK9 protein</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>High Density Lipoprotein cholesterol efflux</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Sparkling highly mineral bicarbonated sodium water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.25 liter a day of sparkling highly mineral bicarbonated sodium water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sparkling low mineralized water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1.25 liter a day of sparkling low mineralized water</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sparkling highly mineral bicarbonated sodium water</intervention_name>
    <description>1,25 liter a day at the mealtimes</description>
    <arm_group_label>Sparkling highly mineral bicarbonated sodium water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 to 70 years (limits included) ;

          -  With a BMI between 18,5 (limit excluded) and 35 kg/m² (limit excluded) ;

          -  Menopausal female without hormone replacement therapy or with stable hormone
             replacement therapy since at least 3 months or non-menopausal female with reliable
             contraception since at least two cycles before the beginning of the study and agreeing
             to keep it during the entire duration of the study;

          -  Without changes in food habits and physical activity during the last 3 months and
             agreeing not to change them throughout the study

          -  Tolerating sparkling mineral water consumption instead of usual water during 8 weeks

          -  Fasting blood triglycerides level between 1 and 3,5 g/L (limits included);

          -  Fasting total cholesterol &lt; 3g/L;

          -  Fasting blood glucose level &lt; 1,26 g/L.

        Exclusion Criteria:

          -  Known or suspected food allergy or intolerance to one of the tested products'
             components or to related products ;

          -  Consuming more than 2 alcoholic drinks daily;

          -  Smoking more than 10 cigarettes daily ;

          -  Following an extreme or exclusive diet (vegetarian, vegan ...)

          -  With personal history of anorexia nervosa, bulimia or eating disorders;

          -  With a body weight variation &gt; 5 kg in the last 3 months;

          -  Having a lifestyle deemed incompatible with the study according to the investigator;

          -  With metabolic disorders such as diabetes or other chronic severe disease ;

          -  Suffering from uncontrolled hypertension;

          -  With severe chronic disease (cancer, HIV, renal failure, liver disorders ongoing,
             chronic inflammatory digestive disease, arthritis or other chronic respiratory
             failure, etc.) or gastrointestinal disorders found to be inconsistent with the conduct
             of the study by the investigator ;

          -  Pregnant or breastfeeding women or intending to become pregnant within 4 months ahead
             ;

          -  Under lipid-lowering therapy or stopped for less than 6 weeks for statins or fibrates
             and less than 6 months for niacin;

          -  Eating foodstuffs or dietary supplements that may interfere with lipid metabolism (red
             yeast rice, policosanol, omega-3 fatty acids, plant stanol or sterol) or consuming
             them steadily over the last 4 weeks;

          -  Using of medications which could affect lipid absorption or/and metabolism (long-term
             corticosteroid treatment);

          -  Using a treatment which may interfere with the evolution of the parameters studied
             according to the investigator;

          -  Who made a blood donation in the last 3 months or intending to make it within 4 months
             ahead ;

          -  Taking part in an-other clinical trial or being in the exclusion period of a previous
             clinical trial.

        A re-screening can occur from 2 months after the exit of study for failure to comply with
        the one or more of the eligibility criteria listed above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gendre, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioFortis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OPTIMED</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naturalpha</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biofortis</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2013</study_first_posted>
  <last_update_submitted>July 28, 2014</last_update_submitted>
  <last_update_submitted_qc>July 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood triglyceride</keyword>
  <keyword>Bicarbonated mineral wate</keyword>
  <keyword>Post-prandial triglyceridemia</keyword>
  <keyword>lipid metabolism</keyword>
  <keyword>Cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

